2. Cell Cycle/DNA Damage Metabolic Enzyme/Protease Protein Tyrosine Kinase/RTK JAK/STAT Signaling PI3K/Akt/mTOR Apoptosis
  3. HSP EGFR Akt Survivin
  4. 3034605-72-3

3034605-72-3

HVH-2930 Chemical Structure

3034605-72-3

Chemical Structure

  • HVH-2930
  • CAS No: 3034605-72-3
    Formula: C29H36N4O3
    Molecular Weight: 488.62
  • InChIKey: DBAWJYXZNCEOOW-UHFFFAOYSA-N
  • SMILES: O=C(C1=C(OC)C(C=CC(C)(C)O2)=C2C=C1)NC3=CC4=C(C=C3)C(C)=NN4CCC5CCN(C)CC5

Biological Activity: HVH-2930 is an inhibitor for heat shock protein 90 (HSP90). HVH-2930 inhibits cell viability of BT474 (Trastuzumab (HY-P9907) sensitive) and JIMT-1 (Trastuzumab (HY-P9907) resistant), with IC50 of 6.86 μM and 4.42 μM, through downregulation of HSP90 clients HER2, p-HER2, AKT, p-AKT, cyclin D1 and survivin. HVH-2930 exhibits antitumor efficacy in mouse models. HVH-2930 exhibits good pharmacokinetic characteristics in mice[1].

Cat. No. Product Name Purity Description
HY-161781 HVH-2930 HVH-2930 is an inhibitor for heat shock protein 90 (HSP90). HVH-2930 inhibits cell viability of BT474 (Trastuzumab (HY-P9907) sensitive) and JIMT-1 (Trastuzumab (HY-P9907) resistant), with IC50 of 6.86 μM and 4.42 μM, through downregulation of HSP90 clients HER2, p-HER2, AKT, p-AKT, cyclin D1 and survivin. HVH-2930 exhibits antitumor efficacy in mouse models. HVH-2930 exhibits good pharmacokinetic characteristics in mice.

References

[1]. La M T, et al. Discovery of Indazole Inhibitors for Heat Shock Protein 90 as Anti-Cancer Agents[J]. European Journal of Medicinal Chemistry, 2024: 116620.

Keywords:

HVH-2930